Diabetic retinopathy is caused due to chronic diabetic disease, in which target organ is retina of the eye. It is a life threatening disease of the retinal microvasculature associated with the prolonged hyperglycaemia and other conditions linked to diabetes mellitus such as hypertension. Diabetic retinopathy is the leading cause of blindness in many countries and the World Health Organization estimates that nearly 5% of the 37 million cases of blindness are suffering from loss of vision due to diabetes in the world. According to Wisconsin Epidemiological Study of Diabetic Retinopathy, more than 75% of diabetics of more than 20 years progression have some form of retinopathy.
The factors which are boosting the growth of global diabetic retinopathy markets are growing incidence of diabetes across globe, increasing incidence of complication associated with diabetes, increase in number of geriatric population globally, awareness regarding diagnosis of diabetic retinopathy, sedentary lifestyle, urbanization associated with changes in eating habits and genetic composition, unhealthy lifestyle, rising obesity and non-compliance to maintaining a healthy lifestyle post diagnosis is becoming pandemic. High cost associated with the treatment of retinopathy is hindering the demand for global diabetic retinopathy.
According to the World Health Organization, the diabetic epidemic is estimated to account for nearly 300 million people suffering from diabetes in 2025. Improved medical care of diabetic patients increased life expectancy that will result in reduce number of complications associated with diabetic such as blindness, strokes etc. Several innovative therapeutic approaches are being researched by the R& D department of companies for better treatment and prevention of diabetic retinopathy.
Do Inquiry of the Report Here: https://marketresearch.biz/report/diabetic-retinopathy-market/#inquiry
The global diabetes retinopathy market is segmented on the basis of product type, therapy and region. On the basis of region, market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America dominates the global diabetic retinopathy market owing to reasons of growing incidence of diabetes. Asia Pacific diabetic retinopathy market is expected to have high CAGR over the forecoming years.
Prominent market players in global diabetes retinopathy market are, Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceuticals Inc., Abbott Laboratories Ltd, Novartis AG, Alimera Sciences Inc., Boehringer Ingelheim GmbH, Vitreoretinal Technologies Inc., Quark Pharmaceuticals Inc., and ThromboGenics Inc.